Transforming Cancer Therapy
With Precision Epigenetics.

Our Mission: To develop a test that offers a clear ‘no-chemotherapy’ decision to patients who are unlikely to benefit from chemotherapy, and to guide them toward the best alternative treatment options.

Episteme Prognostics

Two Key Programs

  • PancEpistemeDxTM

Predicts chemotherapy non-response with >90% accuracy using patented chromatin accessibility technology.

  • PancEpisteme DX DuoTM

Combines chemotherapy response prediction and companion diagnostic in a single assay.

Next generation of personalized treatment strategies

  • Episteme’s platform

Episteme’s platform is able to identify patients who will respond to chemotherapy, and who won’t—and then guide them to a better alternate path. Our goal is to enable the next generation of personalized treatment strategies—beginning with pancreatic cancer and extending far beyond.

  • Epigenetic modulators

Epigenetic modulators are gaining significant momentum and are rapidly progressing through clinical trials. Our technology has the potential to identify patients most likely to respond to these novel therapies, thereby increasing the likelihood of success in clinical trials involving epigenetic drugs. As a result, our platform is ideally positioned to partner with biopharmaceutical companies in the development of companion diagnostics (CDx) for epigenetic treatments.

  • Episteme’s pioneering

Episteme’s pioneering science and technology has demonstrated the ability to predict chemotherapy response in patients with pancreatic cancer using Accessible Chromatin Region (ACR) signature (Dhara et al, Nature Communications 2021) with 99% accuracy for identifying non-responders to chemotherapy in pancreatic cancer.

  • Episteme’s breakthrough

Our breakthrough development is targeted Chromatin Accessibility and Mutation –sequencing (tCAM-seq), a deep-sequencing-based advanced platform technology, which enables the simultaneous detection of both actionable mutations and actionable ACR signatures — all from a single panel, using a single specimen.